Table 3.

Clinical outcomes

	Avalus	Magna	p value
Survival period (months)	16.0 [5.5, 20.0]	74.0 [47.0, 113]	< 0.001
In hospital MACCEs	2 (2.3)	14 (3.7)	0.75
In-hospital mortality (cardiac)	0	2 (0.5)
Cerebrovascular accidents	1 (1.1)	4 (1.0)
Permanent pacemaker implant	1 (1.1)	6 (1.6)
Heart failure	0	1 (0.3)
Perioperative myocardial infarction	0	1 (0.3)
1-year MACCEs	1 (1.1)	9 (2.5)	0.69
1-year mortality	0	2 (0.5)
Cerebral hemorrhage	0	1 (0.3)
Unknown	0	1 (0.3)
Cerebrovascular accidents	0	2 (0.5)
Permanent pacemaker implant	0	1 (0.3)
Heart failure	1 (1.1)	2 (0.5)
Re-intervention due to PVE	0	2 (0.5)

Data are presented as median [interquartile range] or number (%). MACCEs, major adverse cardiac and cerebrovascular events; PVE, prosthetic valve endocarditis; LVDd, left ventricular internal diameter in diastole; LVDs, left ventricular internal diameter in systole; LVEF, left ventricular ejection fraction; PPM, patient–prosthesis mismatch